We are live on ! Find out more
AURA icon

Aura Biosciences

104 hedge funds and large institutions have $317M invested in Aura Biosciences in 2025 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 32 increasing their positions, 29 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

73% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 15

37% more capital invested

Capital invested by funds: $232M → $317M (+$85.3M)

21.35% more ownership

Funds ownership: 79.35%100.69% (+21%)

11% more funds holding

Funds holding: 94104 (+10)

10% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 29

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

Holders
104
Holders Change
+10
Holders Change %
+10.64%
% of All Funds
1.37%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
26
Increased
32
Reduced
29
Closed
15
Calls
$4K
Puts
Net Calls
+$4K
Net Calls Change
+$6K
Name Holding Trade Value Shares
Change
Change in
Stake
MCMC
1
Matrix Capital Management Company
New Hampshire
$43.3M
FLSM
2
Frazier Life Sciences Management
California
$31.9M +$29.8M +5,100,000 New
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$30.6M
LFCM
4
Long Focus Capital Management
Puerto Rico
$28.9M +$7.6M +1,300,000 +39%
SCM
5
Suvretta Capital Management
New York
$27.4M +$9.6M +1,640,998 +60%
BlackRock
6
BlackRock
New York
$19.4M -$2.56M -437,424 -12%
MVM
7
Medicxi Ventures Management
Jersey
$19M
Vanguard Group
8
Vanguard Group
Pennsylvania
$15.5M +$3.07M +525,169 +27%
Franklin Resources
9
Franklin Resources
California
$14.7M +$762K +130,221 +6%
NCM
10
Nantahala Capital Management
Connecticut
$13.3M +$4.97M +850,000 +67%
LCS
11
Levin Capital Strategies
New York
$9.36M +$788K +134,792 +10%
SB
12
Samsara BioCapital
California
$6.26M +$5.85M +1,000,000 New
Geode Capital Management
13
Geode Capital Management
Massachusetts
$5.82M -$559K -95,582 -9%
UBS Group
14
UBS Group
Switzerland
$5.58M +$806K +137,870 +18%
State Street
15
State Street
Massachusetts
$5.36M +$369K +63,175 +8%
RCM
16
Regency Capital Management
Hawaii
$4.17M -$489K -83,601 -11%
ACA
17
Acorn Capital Advisors
New York
$3.73M +$30.6K +5,236 +0.9%
BGI
18
B Group Inc
Texas
$3.58M +$585K +100,000 +21%
DC
19
Decheng Capital
California
$3.23M
T. Rowe Price Associates
20
T. Rowe Price Associates
Maryland
$3.16M -$87.5K -14,957 -3%
Dimensional Fund Advisors
21
Dimensional Fund Advisors
Texas
$2.86M +$294K +50,231 +12%
Northern Trust
22
Northern Trust
Illinois
$2.32M -$23.7K -4,046 -1%
Goldman Sachs
23
Goldman Sachs
New York
$1.33M +$530K +90,654 +75%
CP
24
Caligan Partners
New York
$1.25M +$1.17M +200,000 New
Wellington Management Group
25
Wellington Management Group
Massachusetts
$1.19M +$296K +50,533 +36%

AURA Hedge Fund Activity: Q2 2025 in Review

104 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Aura Biosciences (AURA) for Q2 2025, worth a combined $317M — up 37% from $232M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new AURA positions and 15 closed out — a net gain of 11 holders — while 32 added to existing stakes and 29 trimmed.

The largest buyer was Frazier Life Sciences Management, opening a new position worth an estimated $29.8M. The largest seller was BlackRock, cutting an estimated $2.56M.

  • 104 institutional investors held Aura Biosciences (AURA) as of Q2 2025, up from 94 in Q1 2025.
  • Funds reported $317M of Aura Biosciences stock for Q2 2025, up 37% quarter-over-quarter.
  • 26 funds opened new Aura Biosciences positions in Q2 2025 and 15 closed out, a net change of +11 holders.
  • The largest Aura Biosciences buyer in Q2 2025 was Frazier Life Sciences Management, an estimated $29.8M added.
  • The largest Aura Biosciences seller in Q2 2025 was BlackRock, an estimated $2.56M sold.

Based on aggregated 13F filings for Q2 2025.